Biogen Idec to acquire full rights and control of TYSABRI® from Elan for upfront cash and contingent payments
6 February 2013 | By Biogen Idec
Biogen Idec has agreed to purchase Elan’s interest in TYSABRI...
List view / Grid view
6 February 2013 | By Biogen Idec
Biogen Idec has agreed to purchase Elan’s interest in TYSABRI...
24 January 2013 | By Biogen Idec
Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial...
16 January 2013 | By Biogen Idec
Biogen Idec and Elan have submitted applications to the U.S. FDA...
4 January 2013 | By Biogen Idec
Half-life of long-lasting rFIXFc may enable prophylactic dosing every 1-2 weeks...
3 January 2013 | By Biogen Idec
EMPOWER trial fails to demonstrate efficacy in primary and key secondary endpoints...
20 December 2012 | By Biogen Idec
Biogen Idec has created a new research consortium...
12 December 2012 | By Biogen Idec
Biogen Idec and Eisai Inc. announced a strategic alliance...
29 November 2012 | By Biogen Idec
Biogen Idec dedicated a new facility in Research Triangle Park (RTP), consolidating its 300-person Patient Services operation with the existing RTP campus...
31 October 2012 | By Biogen Idec
Biogen Idec and Swedish Orphan Biovitrum announced positive results from A-LONG...
18 October 2012 | By Biogen Idec
Biogen Idec announced that the U.S. FDA has extended the initial PDUFA date for its review...
17 October 2012 | By Biogen Idec
Biogen Idec announced that the U.S. FDA has extended the initial PDUFA date...
12 October 2012 | By Biogen Idec
New data from studies evaluating oral BG-12...
11 October 2012 | By Biogen Idec
Results from 11 company-sponsored TYSABRI presentations...
10 October 2012 | By Biogen Idec
Extensive data from MS franchise...
12 September 2012 | By Biogen Idec
The Biogen Idec Foundation has awarded the Museum of Science, Boston a $1 million grant...